The landmark ECHELON-1 study demonstrated that the A+AVD regimen offers a superior OS benefit. Solidified by 7 years of robust data, A+AVD now sets the new standard of care, fundamentally improving the long-term prognosis for patients.

In the 64th American Society of Hematology (ASH) Annual Meeting and Exposition 2022, Dr. Stefan K. Alig, from Stanford University, the United States, shared his group’s study on the distinct molecular subtypes of classic Hodgkin lymphoma (cHL) identified by comprehensive noninvasive profiling.1 Pat

The combination treatment approach of chemotherapy and radiotherapy has significantly improved the survival outcomes of patients with Hodgkin lymphoma (HL) over the past several decades.¹ Whereas the conventional frontline therapies, such as ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine), c

Hodgkin lymphoma (HL) is an aggressive hematological malignancy, with around 70 new cases being reported per year in Hong Kong.¹ The incidence rate for HL among people aged 65 or above in Hong Kong is 1.6 per 100,000 persons.¹